title: [Treatment results of patients over 3 years of age with medulloblastoma].
abstract: THE AIM of the study was to assess the survival of patients with medulloblastoma (MB)/PNET treated according to own protocol and to compare it with the earlier treatment protocol group.
  
  
  METHODS
  Analysis of 77 patients was undertaken. For the purpose of this study we divided our patients into 2 groups. First group consisted of 34 patients (21 high risk, 12 standard risk, 1 unknown) treated with surgery and radiotherapy and surgery followed by chemo- and radiotherapy. Among the second group including 43 patients (23 HRMB, 6 SRMB, 11 supratentorial PNET's, 3 unknown) treated according to own protocol since 1997. Surgery was performed in all patients. 4 courses of chemotherapy were administered (VCR, VP, CBDCA, CTX, IF, CDDP) and craniospinal irradiation was implemented. Maintenance chemotherapy consisting of 8 courses of VCR, CDDP, CCNU, was given. Event free survival (EFS) in two groups and in high-risk patients of both groups were compared.
  
  
  RESULTS
  In the earlier treated group 4 yrs EFS was 50% versus 78% in recently treated patients. In high-risk patients 4 yrs EFS was 40% (with no plateau on the curve) in the historical group and 76% in currently treated.
  
  
  CONCLUSIONS
  Introduction of our protocol resulted in marked improvement of treatment results, especially since most of our patients were in the high-risk group.
authors.affiliation: Klinika Onkologii, Instytut Pomnik Centrum Zdrowia Dziecka, al. Dzieci Polskich 20, 04-730 Warszawa, Poland.
authors.forename: Danuta
authors.initials: D
authors.lastname: Perek
authors.forename: Marta
authors.initials: M
authors.lastname: Perek-Polnik
authors.forename: Monika
authors.initials: M
authors.lastname: Drogosiewicz
authors.forename: Bozenna
authors.initials: B
authors.lastname: Dembowska-Bagińska
authors.forename: Sławomir
authors.initials: S
authors.lastname: Barszcz
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008527:Medulloblastoma / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D018714:Radiotherapy, Adjuvant; D012008:Recurrence; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome